Blue Jet Healthcare Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/bt5gcwfi4s6v765ughhrqysg.pdf

Key Takeaways


Contrast Media: The Transit Distortion

Shiven Arora: "While quarterly variations are natural, our medium to long term visibility is strong, fueled by order book momentum, customer lock-ins, new validations and upcoming commercial milestones."

PI-API & the Cardiovascular Intermediate

V.K. Singh: "The molecule is growing very fast. So, there is space for us and for any other competitor. The other thing is that we are protected with long-term contracts. And if you see the data, the primary source of supply is us, besides the opportunity is extremely big and the triple combination could be a game changer."

Chronic Disease Pipeline: The Next Leg


Sweeteners: The Replication Play

Shiven Arora: "What we have done in Saccharin, we want to replicate the same strategy. And what we had done in Saccharin, we were trying to capture 10% of the world market. Over here also, our endeavor would be to reach to that 10% in a long-term vision."

Capacity Build-Out: Mahad & Vizag

V.K. Singh: "With this plant going on stream, we strengthen our position as a credible and leading global supplier of CMI to all the leading innovator companies in this segment... we achieve not only strategic independence but also insulate the business from significant volatility that we have in key raw material prices."

Margins & Financials


Guidance & Commitments

CommitmentSpecificsTimeline
Mahad backward integration commissioningSite to go live; flow synthesis for CMI KSMsH2 FY26
New iodinated intermediate commercializationCommercial supply beginsQ4 FY26
Three Onco/CNS late-stage candidatesCommercialization targetedFY '27
Other chronic molecules meaningful contributionRevenue contribution beginsFY '27 and beyond
Vizag Phase-I completionCapacity for contrast media and sweetenersFY '28
Total capacity additionAdditional 1,000 KL across Mahad and Vizag2-3 years
Full-year EBITDAEndeavor to maintain ~35%FY26
PI-API full-year growthSlight growth based on order bookFY26
New Sweetener long-term market share10% of world marketLong-term (no date)

Key Metrics

MetricQ2 FY26
Revenue from operations₹165 cr, down 54% QoQ and 21% YoY
H1 FY26 revenue from operations₹518 cr, up 40% YoY
EBITDA₹60.1 cr, 36% margin, up 14% YoY
EBITDA margin33%, down 1 ppt sequentially
H1 FY26 EBITDA₹182 cr, 35% margin, up 41% YoY
PAT₹43.2 cr, 26% margin
PAT margin32%, up 6 ppt sequentially
H1 FY26 PAT₹134.2 cr, up 36% YoY
Other income₹24 cr, primarily exchange gain and return on short-term investments
Gross margin65%, versus 48% in Q1 FY26
H1 FY26 gross margin54%
Contrast Media revenue₹81 cr, down 17% QoQ
Contrast Media H1 FY26 revenue₹178 cr, flat YoY
Pharma Intermediates and API revenue₹42 cr, down 80% QoQ
Pharma Intermediates and API H1 FY26 revenue₹255 cr, up 113% YoY
High-intensity Sweeteners growth7% sequential growth in Q2
High-intensity Sweeteners H1 FY26 growth3% YoY
Cash and liquid investments₹341 cr, debt-free
H1 FY26 CAPEX incurred~₹135 cr
Annualized capacity utilization60%–65%, expected to stay in that range
US revenue shareLess than 5% of overall revenues
Bempedoic Acid molecule growth10%–15% QoQ in the last quarter
Transit time for Contrast Media shipments60 days, up from 35–40 days previously
Share of Q2 Contrast Media production recognized as sale55%, remainder in transit to be recognized in subsequent quarter